Initiation and Regulation of Antiviral Innate Immunity

Information

  • Research Project
  • 10475431
  • ApplicationId
    10475431
  • Core Project Number
    R56AI093589
  • Full Project Number
    2R56AI093589-11A1
  • Serial Number
    093589
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    3/1/2011 - 13 years ago
  • Project End Date
    8/31/2022 - 2 years ago
  • Program Officer Name
    SINGLETON, KENTNER L
  • Budget Start Date
    9/13/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    11
  • Suffix
    A1
  • Award Notice Date
    9/13/2021 - 3 years ago

Initiation and Regulation of Antiviral Innate Immunity

Project Summary The goal of this proposal is to identify how the pattern recognition receptor cyclic GMP-AMP synthase (cGAS) operates as a high-fidelity DNA sensor that drives interferon (IFN) and inflammatory responses. In humans and mice, cGAS synthesizes the second messenger cyclic GMP-AMP (cGAMP) upon binding DNA. This second messenger stimulates immune responses upon binding the downstream regulatory protein STING. As such, cGAMP is considered a next-generation adjuvant. Because cGAS detects the sugar-phosphate backbone of double stranded DNA, a major question relates to how this enzyme is regulated to ensure inflammatory responses are selectively generated in response to viral (but not self) DNA. All cGAS proteins in nature contain a C-terminal catalytic domain that is necessary and sufficient for DNA binding and cGAMP production. All cGAS proteins also contain an N-terminal domain of poorly defined function. In the previous funding period, we discovered that the cGAS N-terminal domain functions to prevent self-DNA reactivity within human cells. Despite this insight into cGAS regulation, much remains unclear about its activities in infectious and non-infectious contexts. Indeed, we have discovered striking species-specific diversity of regulatory mechanisms that control cGAS activities. Understanding regulatory events that drive cGAS-mediated inflammatory responses will enable discussions of how protective immunity can be stimulated against infection and cancer. In this application, we propose to leverage natural cGAS diversity to explain the mechanisms of DNA-induced IFN responses (Aim 1), and leverage synthetic biology to further diversify cGAS into a ?guard protein?, which provides a novel means of probing host-virus interaction (Aim 2).

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R56
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
    300000
  • Indirect Cost Amount
    231000
  • Total Cost
    531000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:531000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    III
  • Study Section Name
    Innate Immunity and Inflammation Study Section
  • Organization Name
    BOSTON CHILDREN'S HOSPITAL
  • Organization Department
  • Organization DUNS
    076593722
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021155724
  • Organization District
    UNITED STATES